KR20090031855A - 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과조합된 ｃ-ｓｒｃ 억제제의 용도 - Google Patents

백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과조합된 ｃ-ｓｒｃ 억제제의 용도 Download PDF

Info

Publication number
KR20090031855A
KR20090031855A KR1020087027245A KR20087027245A KR20090031855A KR 20090031855 A KR20090031855 A KR 20090031855A KR 1020087027245 A KR1020087027245 A KR 1020087027245A KR 20087027245 A KR20087027245 A KR 20087027245A KR 20090031855 A KR20090031855 A KR 20090031855A
Authority
KR
South Korea
Prior art keywords
compound
leukemia
formula
combination
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087027245A
Other languages
English (en)
Korean (ko)
Inventor
폴 더블유. 맨리
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20090031855A publication Critical patent/KR20090031855A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087027245A 2006-04-07 2007-04-05 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과조합된 ｃ-ｓｒｃ 억제제의 용도 Ceased KR20090031855A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79043706P 2006-04-07 2006-04-07
US60/790,437 2006-04-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020117016784A Division KR101292508B1 (ko) 2006-04-07 2007-04-05 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도

Publications (1)

Publication Number Publication Date
KR20090031855A true KR20090031855A (ko) 2009-03-30

Family

ID=38512209

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087027245A Ceased KR20090031855A (ko) 2006-04-07 2007-04-05 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과조합된 ｃ-ｓｒｃ 억제제의 용도
KR1020117016784A Expired - Fee Related KR101292508B1 (ko) 2006-04-07 2007-04-05 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117016784A Expired - Fee Related KR101292508B1 (ko) 2006-04-07 2007-04-05 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도

Country Status (11)

Country Link
US (2) US20100152198A1 (enExample)
EP (1) EP2010182A2 (enExample)
JP (2) JP2009532438A (enExample)
KR (2) KR20090031855A (enExample)
CN (1) CN101415426A (enExample)
AU (1) AU2007235976A1 (enExample)
BR (1) BRPI0710675A2 (enExample)
CA (1) CA2644841C (enExample)
MX (1) MX2008012903A (enExample)
RU (2) RU2008143703A (enExample)
WO (1) WO2007116025A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) * 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CN103113355B (zh) * 2013-02-27 2014-08-13 无锡爱内特生物科技有限公司 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
CN116178358B (zh) * 2022-11-04 2024-04-19 济南大学 一种靶向c-Src激酶SH3结构域的化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690773A5 (de) * 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US7238525B2 (en) * 2000-06-30 2007-07-03 The Regents Of The University Of California Strategy for leukemia therapy
WO2002062334A2 (en) * 2001-02-05 2002-08-15 Pezzuto John M Cancer chemopreventative compounds and compositions and methods of treating cancers
ATE431417T1 (de) * 2001-06-14 2009-05-15 Univ California Mutationen in der mit der resistenz gegenüber sti-571 assoziierten bcr-abl-tyrosinkinase
EP2258371A1 (en) * 2001-08-10 2010-12-08 Novartis AG Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
EP1473043A1 (en) * 2003-04-29 2004-11-03 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
AU2003291245A1 (en) * 2003-11-06 2004-06-06 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
US20060069101A1 (en) * 2004-09-27 2006-03-30 Kim Kyoung S Prodrugs of protein tyrosine kinase inhibitors
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida

Also Published As

Publication number Publication date
CA2644841A1 (en) 2007-10-18
RU2008143703A (ru) 2010-05-20
WO2007116025A2 (en) 2007-10-18
JP2013136596A (ja) 2013-07-11
JP2009532438A (ja) 2009-09-10
KR20110097966A (ko) 2011-08-31
RU2012147511A (ru) 2014-05-20
WO2007116025A3 (en) 2007-12-13
AU2007235976A1 (en) 2007-10-18
US20130040972A1 (en) 2013-02-14
EP2010182A2 (en) 2009-01-07
US20100152198A1 (en) 2010-06-17
MX2008012903A (es) 2008-10-13
CA2644841C (en) 2013-07-16
KR101292508B1 (ko) 2013-08-01
BRPI0710675A2 (pt) 2011-08-23
CN101415426A (zh) 2009-04-22

Similar Documents

Publication Publication Date Title
KR101292508B1 (ko) 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도
CA2450777C (en) Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
JP4827737B2 (ja) アミロイド関連疾患の処置のためのピリジニル−ピリミジニルアミノ−ベンズアミド誘導体の使用
US20080255171A1 (en) Combination of Nilotinib with Farnesyl Transferase Inhibitors
US20110281902A1 (en) Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag
EP2007391B1 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
AU2011202950B2 (en) Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
WO2007051862A1 (en) Combination of organic compounds
KR20080036992A (ko) 증식성 질환을 치료하기 위한 피리미딜아미노벤즈아미드 및ｆｌｔ-3 억제제를 포함하는 조합물
AU2013201915A1 (en) Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP2186514B1 (en) Treatment of Malignant Peripheral Nerve Sheath Tumors
KR20070106036A (ko) Ｂｃｒ-ａｂｌ 및 ｒａｆ 억제제의 제약 조합물
HK1146804A (en) Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
CN101484172A (zh) 包含a)嘧啶基氨基苯甲酰胺化合物和b)thr315lle激酶抑制剂的组合

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090716

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110317

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20110718

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120119

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110317

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20120224

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20120119

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20130523

Appeal identifier: 2012101001932

Request date: 20120224

J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

Appeal kind category: Appeal against decision to decline refusal

Request date: 20120224

Decision date: 20130523

Appeal identifier: 2012101001932

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20120224

Effective date: 20130523

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20130523

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20120224

Decision date: 20130523

Appeal identifier: 2012101001932

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20130723

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20130723

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2012101001932

Request date: 20120224

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20130523

WITB Written withdrawal of application